Dr. Maximilien Murone COO Cellestia Biotech AG, Basel "Development of CB-103 for Targeted Therapy of NOTCH-Driven Cancers: from Bench-to-Bedside"
Sorry, JavaScript must be enabled.Change your browser options, then try again.